Minnow Street Minnow Street
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Oric Pharmaceuticals Inc (ORIC)

Healthcare Biotechnology
11.10 $
-4.9% vs. previous close
Closing price · As of: 31. Jul 2026

Who owns Oric Pharmaceuticals Inc (ORIC)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 79.9% of the shares are freely tradable; institutional investors hold 114.2%.

Ownership Structure

Institutional ownership
114.2%
Insiders
5.9%
Float
79.9%
Short % of float
20.6%
Shares Outstanding
104Mio.

Largest Shareholders

Institutions

Institutions ORIC
Name Stake (%) Shares Change (%) Date
Nextech Invest, Ltd. 6.92 7,162,637 +0.0 12/31/2025
EcoR1 Capital, LLC 6.50 6,728,116 +0.0 03/31/2026
BlackRock Inc 5.78 5,984,552 +1.9 03/31/2026
Viking Global Investors LP 5.63 5,824,533 -11.4 03/31/2026
T. Rowe Price Associates, Inc. 5.20 5,387,783 +63.5 03/31/2026
Pfizer Inc 4.62 4,780,401 -11.1 03/31/2026
Vanguard Group Inc 4.39 4,541,974 -2.3 12/31/2025
SR ONE CAPITAL MANAGEMENT, LP 4.36 4,514,929 +0.0 12/31/2025
Alkeon Capital Management, LLC 4.35 4,504,096 +0.0 03/31/2026
VR Adviser, LLC 4.17 4,319,765 -23.9 03/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
24. Jul 2026 Heyman Richard A. Director Sell 6,100 12.02 73,322
24. Jul 2026 Heyman Richard A. Director Sell 7,000 12.02 84,140
24. Jul 2026 Heyman Richard A. Director Other 3,500 1.60 5,600
6. Jul 2026 Heyman Richard A. Director Sell 300 12.00 3,600

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?